Different research groups have already reported the overexpression of MYL6B in CD133+ hematopoietic stem cell in leukemia [28], in HBV related HCC [29], in HCC cell lines [30] and correlated to the prognosis of leukemia patients [31]. This evidence concerns the gene PROM1 and hepatocellular carcinoma.